{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T18:49:56Z","timestamp":1767898196272,"version":"3.49.0"},"reference-count":42,"publisher":"American Academy of Pediatrics (AAP)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2009,2,1]]},"abstract":"<jats:p>OBJECTIVES. The prevalence and identification of hypertriglyceridemia in youths will likely will increase in the future as a consequence of childhood obesity and increased screening for dyslipidemias. We sought to review our clinical experience with hypertriglyceridemia, evaluate factors associated with increased triglyceride levels, and review treatment options to provide guidance for management.<\/jats:p>\n               <jats:p>METHODS. Clinical review of data for all patients who had \u22651 elevated triglyceride level (&amp;gt;4 mmol\/L [&amp;gt;350 mg\/dL]) while being monitored in a specialized lipid disorders clinic was performed.<\/jats:p>\n               <jats:p>RESULTS. The study population consisted of 76 patients with 761 clinic visits. Hypertriglyceridemia was secondary to lifestyle factors for 13 patients. The rest had primary hypertriglyceridemia, with 32 patients having familial combined hypertriglyceridemia and hypercholesterolemia (type II), 25 patients having primary hypertriglyceridemia (type IV), 4 patients having familial lipase deficiency (type I), and 2 patients having hyperlipoproteinemia E2\/E2 phenotype (type III). Triglyceride levels were highest in type I and III hypertriglyceridemia (&amp;gt;10 mmol\/L [&amp;gt;900 mg\/dL]), followed by type IV and adiposity-related hypertriglyceridemia (&amp;gt;4 mmol\/L [&amp;gt;350 mg\/dL]) and finally type II familial combined hypertriglyceridemia and hypercholesterolemia (&amp;gt;2 mmol\/L [&amp;gt;180 mg\/dL]). A total of 34 patients received 37 trials of drug therapy as part of triglyceride level management (bile acid\u2013binding resins, n = 12; fibrates, n = 19; statins, n = 6). Triglyceride levels were found to decrease over time with the use of fibrates, to increase with the use of bile acid\u2013binding resins, and not to change with the use of statins.<\/jats:p>\n               <jats:p>CONCLUSIONS. Lifestyle modifications remain the primary therapeutic avenue for the management of pediatric hypertriglyceridemia. We propose an algorithm for the management of this heterogeneous population to guide clinicians in their treatment decisions.<\/jats:p>","DOI":"10.1542\/peds.2008-0367","type":"journal-article","created":{"date-parts":[[2009,1,26]],"date-time":"2009-01-26T12:23:44Z","timestamp":1232972624000},"page":"458-465","source":"Crossref","is-referenced-by-count":52,"title":["Spectrum and Management of Hypertriglyceridemia Among Children in Clinical Practice"],"prefix":"10.1542","volume":"123","author":[{"given":"Cedric","family":"Manlhiot","sequence":"first","affiliation":[{"name":"Division of Cardiology, Labatt Family Heart Centre, Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Per","family":"Larsson","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Labatt Family Heart Centre, Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rebecca C.","family":"Gurofsky","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Labatt Family Heart Centre, Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryan W.","family":"Smith","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Labatt Family Heart Centre, Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine","family":"Fillingham","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Labatt Family Heart Centre, Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nadia A.","family":"Clarizia","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Labatt Family Heart Centre, Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nita","family":"Chahal","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Labatt Family Heart Centre, Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph T.","family":"Clarke","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Labatt Family Heart Centre, Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian W.","family":"McCrindle","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Labatt Family Heart Centre, Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"417","published-online":{"date-parts":[[2009,2,1]]},"reference":[{"key":"2021120822540676900_R1","doi-asserted-by":"crossref","unstructured":"Merkel M, Eckel RH, Goldberg IJ. Lipoprotein lipase: genetics, lipid uptake, and regulation. J Lipid Res.\u20082002;43(12):1997\u20132006","DOI":"10.1194\/jlr.R200015-JLR200"},{"key":"2021120822540676900_R2","doi-asserted-by":"crossref","unstructured":"Yuan G, Al-Shali KZ, Hegele RA. Hypertriglyceridemia: its etiology, effects and treatment. CMAJ.\u20082007;176(8):1113\u20131120","DOI":"10.1503\/cmaj.060963"},{"key":"2021120822540676900_R3","doi-asserted-by":"crossref","unstructured":"Boyd GS, Koenigsberg J, Falkner B, Gidding S, Hassink S. Effect of obesity and high blood pressure on plasma lipid levels in children and adolescents. Pediatrics.\u20082005;116(2):442\u2013446","DOI":"10.1542\/peds.2004-1877"},{"key":"2021120822540676900_R4","doi-asserted-by":"crossref","unstructured":"Garce\u0301s C, Gutierrez-Guisado J, Benavente M, et al. Obesity in Spanish schoolchildren: relationship with lipid profile and insulin resistance. Obes Res.\u20082005;13(6):959\u2013963","DOI":"10.1038\/oby.2005.111"},{"key":"2021120822540676900_R5","doi-asserted-by":"crossref","unstructured":"Jacobs MJ, Kleisli T, Pio JR, et al. Prevalence and control of dyslipidemia among persons with diabetes in the United States. Diabetes Res Clin Pract.\u20082005;70(3):263\u2013269","DOI":"10.1016\/j.diabres.2005.03.032"},{"key":"2021120822540676900_R6","unstructured":"Lai SW, Ng KC, Lin HF, Chen HL. Association between obesity and hyperlipidemia among children. Yale J Biol Med.\u20082001;74(4):205\u2013210"},{"key":"2021120822540676900_R7","doi-asserted-by":"crossref","unstructured":"Reinehr T, Andler W, Denzer C, Siegried W, Mayer H, Wabitsch M. Cardiovascular risk factors in overweight German children and adolescents: relation to gender, age and degree of overweight. Nutr Metab Cardiovasc Dis.\u20082005;15(3):181\u2013187","DOI":"10.1016\/j.numecd.2004.06.003"},{"key":"2021120822540676900_R8","doi-asserted-by":"crossref","unstructured":"Sherry N, Hassoun A, Oberfield SE, et al. Clinical and metabolic characteristics of an obese, Dominican, pediatric population. J Pediatr Endocrinol Metab.\u20082005;18(11):1063\u20131071","DOI":"10.1515\/JPEM.2005.18.11.1063"},{"key":"2021120822540676900_R9","doi-asserted-by":"crossref","unstructured":"Berenson GS, Srinivasan SR, Bao W, Newman WP III, Tracy RE, Wattigney WA. Association between multiple cardiovascular risk factors and atherosclerosis in children and young adults: the Bogalusa Heart Study. N Engl J Med.\u20081998;338(23):1650\u20131656","DOI":"10.1056\/NEJM199806043382302"},{"key":"2021120822540676900_R10","doi-asserted-by":"crossref","unstructured":"Celermajer DS, Sorensen KE, Gooch VM, et al. Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet.\u20081992;340(8828):1111\u20131115","DOI":"10.1016\/0140-6736(92)93147-F"},{"key":"2021120822540676900_R11","doi-asserted-by":"crossref","unstructured":"Tonstad S, Joakimsen O, Stensland-Bugge E, et al. Risk factors related to carotid intima-media thickness and plaque in children with familial hypercholesterolemia and control subjects. Arterioscler Thromb Vasc Biol.\u20081996;16(8):984\u2013991","DOI":"10.1161\/01.ATV.16.8.984"},{"key":"2021120822540676900_R12","doi-asserted-by":"crossref","unstructured":"Assmann G, Cullen P, Schulte H. The Munster Heart Study (PROCAM): results of follow-up at 8 years. Eur Heart J.\u20081998;19(suppl A):A2\u2013A11","DOI":"10.1053\/euhj.1998.1086"},{"key":"2021120822540676900_R13","doi-asserted-by":"crossref","unstructured":"Criqui MH, Heiss G, Cohn R, et al. Plasma triglyceride level and mortality from coronary heart disease. N Engl J Med.\u20081993;328(17):1220\u20131225","DOI":"10.1056\/NEJM199304293281702"},{"key":"2021120822540676900_R14","doi-asserted-by":"crossref","unstructured":"Cullen P. Evidence that triglycerides are an independent coronary heart disease risk factor. Am J Cardiol.\u20082000;86(9):943\u2013949","DOI":"10.1016\/S0002-9149(00)01127-9"},{"key":"2021120822540676900_R15","doi-asserted-by":"crossref","unstructured":"Hokanson JE, Austin MA. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. J Cardiovasc Risk.\u20081996;3(2):213\u2013219","DOI":"10.1097\/00043798-199604000-00014"},{"key":"2021120822540676900_R16","doi-asserted-by":"crossref","unstructured":"Hopkins PN, Wu LL, Hunt SC, Brinton EA. Plasma triglycerides and type III hyperlipidemia are independently associated with premature familial coronary artery disease. J Am Coll Cardiol.\u20082005;45(7):1003\u20131012","DOI":"10.1016\/j.jacc.2004.11.062"},{"key":"2021120822540676900_R17","doi-asserted-by":"crossref","unstructured":"Athyros VG, Giouleme OI, Nikolaidis NL, et al. Long-term follow-up of patients with acute hypertriglyceridemia-induced pancreatitis. J Clin Gastroenterol.\u20082002;34(4):472\u2013475","DOI":"10.1097\/00004836-200204000-00020"},{"key":"2021120822540676900_R18","doi-asserted-by":"crossref","unstructured":"Toskes PP. Hyperlipidemic pancreatitis. Gastroenterol Clin North Am.\u20081990;19(4):783\u2013791","DOI":"10.1016\/S0889-8553(21)00513-6"},{"key":"2021120822540676900_R19","doi-asserted-by":"crossref","unstructured":"Yadav D, Pitchumoni CS. Issues in hyperlipidemic pancreatitis. J Clin Gastroenterol.\u20082003;36(1):54\u201362","DOI":"10.1097\/00004836-200301000-00016"},{"key":"2021120822540676900_R20","doi-asserted-by":"crossref","unstructured":"McCrindle BW. Screening and management of hyperlipidemia in children. Pediatr Ann.\u20082000;29(8):500\u2013508","DOI":"10.3928\/0090-4481-20000801-09"},{"key":"2021120822540676900_R21","doi-asserted-by":"crossref","unstructured":"Napoli C, D'Armiento FP, Mancini FP, et al. Fatty streak formation occurs in human fetal aortas and is greatly enhanced by maternal hypercholesterolemia: intimal accumulation of low density lipoprotein and its oxidation precede monocyte recruitment into early atherosclerotic lesions. J Clin Invest.\u20081997;100(11):2680\u20132690","DOI":"10.1172\/JCI119813"},{"key":"2021120822540676900_R22","doi-asserted-by":"crossref","unstructured":"Groner JA, Joshi M, Bauer JA. Pediatric precursors of adult cardiovascular disease: noninvasive assessment of early vascular changes in children and adolescents. Pediatrics.\u20082006;118(4):1683\u20131691","DOI":"10.1542\/peds.2005-2992"},{"key":"2021120822540676900_R23","doi-asserted-by":"crossref","unstructured":"Reinehr T, de Sousa G, Toschke AM, Andler W. Long-term follow-up of cardiovascular disease risk factors in children after an obesity intervention. Am J Clin Nutr.\u20082006;84(3):490\u2013496","DOI":"10.1093\/ajcn\/84.3.490"},{"key":"2021120822540676900_R24","unstructured":"Centers for Disease Control and Prevention. Growth Charts for the United States: Methods and Development. Hyattsville, MD: Department of Health and Human Services; 2000. Report 246"},{"key":"2021120822540676900_R25","doi-asserted-by":"crossref","unstructured":"Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem.\u20081972;18(6):499\u2013502","DOI":"10.1093\/clinchem\/18.6.499"},{"key":"2021120822540676900_R26","doi-asserted-by":"crossref","unstructured":"Austin MA, McKnight B, Edwards KL, et al. Cardiovascular disease mortality in familial forms of hypertriglyceridemia: a 20-year prospective study. Circulation.\u20082000;101(24):2777\u20132782","DOI":"10.1161\/01.CIR.101.24.2777"},{"key":"2021120822540676900_R27","doi-asserted-by":"crossref","unstructured":"Satoh H, Nishino T, Tomita K, Tsutsui H. Fasting triglyceride is a significant risk factor for coronary artery disease in middle-aged Japanese men. Circ J.\u20082006;70(3):227\u2013231","DOI":"10.1253\/circj.70.227"},{"key":"2021120822540676900_R28","doi-asserted-by":"crossref","unstructured":"Avins AL, Neuhaus JM. Do triglycerides provide meaningful information about heart disease risk? Arch Intern Med.\u20082000;160(13):1937\u20131944","DOI":"10.1001\/archinte.160.13.1937"},{"key":"2021120822540676900_R29","doi-asserted-by":"crossref","unstructured":"Crowther NJ, Ferris WF, Ojwang PJ, Rheeder P. The effect of abdominal obesity on insulin sensitivity and serum lipid and cytokine concentrations in African women. Clin Endocrinol (Oxf).\u20082006;64(5):535\u2013541","DOI":"10.1111\/j.1365-2265.2006.02505.x"},{"key":"2021120822540676900_R30","doi-asserted-by":"crossref","unstructured":"Hu D, Hannah J, Gray RS, et al. Effects of obesity and body fat distribution on lipids and lipoproteins in nondiabetic American Indians: the Strong Heart Study. Obes Res.\u20082000;8(6):411\u2013421","DOI":"10.1038\/oby.2000.51"},{"key":"2021120822540676900_R31","doi-asserted-by":"crossref","unstructured":"Sabin MA, Ford AL, Holly JM, Hunt LP, Crowne EC, Shield JP. Characterisation of morbidity in a UK, hospital based, obesity clinic. Arch Dis Child.\u20082006;91(2):126\u2013130","DOI":"10.1136\/adc.2005.083485"},{"key":"2021120822540676900_R32","doi-asserted-by":"crossref","unstructured":"McCrindle BW, Urbina EM, Dennison BA, et al. Drug therapy of high-risk lipid abnormalities in children and adolescents: a scientific statement from the American Heart Association Atherosclerosis, Hypertension, and Obesity in Youth Committee, Council of Cardiovascular Disease in the Young, with the Council on Cardiovascular Nursing. Circulation.\u20082007;115(14):1948\u20131967","DOI":"10.1161\/CIRCULATIONAHA.107.181946"},{"key":"2021120822540676900_R33","doi-asserted-by":"crossref","unstructured":"Jonkers IJ, Smelt AH, Princen HM, et al. Fish oil increases bile acid synthesis in male patients with hypertriglyceridemia. J Nutr.\u20082006;136(4):987\u2013991","DOI":"10.1093\/jn\/136.4.987"},{"key":"2021120822540676900_R34","unstructured":"Balk E, Chung M, Lichtenstein A, et al. Effects of omega-3 fatty acids on cardiovascular risk factors and intermediate markers of cardiovascular disease. Evid Rep Technol Assess (Summ).\u20082004;(93):1\u20136"},{"key":"2021120822540676900_R35","doi-asserted-by":"crossref","unstructured":"Kreisberg RA, Oberman A. Medical management of hyperlipidemia\/dyslipidemia. J Clin Endocrinol Metab.\u20082003;88(6):2445\u20132461","DOI":"10.1210\/jc.2003-030388"},{"key":"2021120822540676900_R36","doi-asserted-by":"crossref","unstructured":"Wheeler KA, West RJ, Lloyd JK, Barley J. Double blind trial of bezafibrate in familial hypercholesterolaemia. Arch Dis Child.\u20081985;60(1):34\u201337","DOI":"10.1136\/adc.60.1.34"},{"key":"2021120822540676900_R37","doi-asserted-by":"crossref","unstructured":"Ginsberg HN. Hypertriglyceridemia: new insights and new approaches to pharmacologic therapy. Am J Cardiol.\u20082001;87(10):1174\u20131180","DOI":"10.1016\/S0002-9149(01)01489-8"},{"key":"2021120822540676900_R38","doi-asserted-by":"crossref","unstructured":"Isaacsohn J, Hunninghake D, Schrott H, et al. Effects of simvastatin, an HMG-CoA reductase inhibitor, in patients with hypertriglyceridemia. Clin Cardiol.\u20082003;26(1):18\u201324","DOI":"10.1002\/clc.4960260105"},{"key":"2021120822540676900_R39","doi-asserted-by":"crossref","unstructured":"McCrindle BW, Helden E, Cullen-Dean G, Conner WT. A randomized crossover trial of combination pharmacologic therapy in children with familial hyperlipidemia. Pediatr Res.\u20082002;51(6):715\u2013721","DOI":"10.1203\/00006450-200206000-00009"},{"key":"2021120822540676900_R40","doi-asserted-by":"crossref","unstructured":"McCrindle BW, O'Neill MB, Cullen-Dean G, Helden E. Acceptability and compliance with two forms of cholestyramine in the treatment of hypercholesterolemia in children: a randomized, crossover trial. J Pediatr.\u20081997;130(2):266\u2013273","DOI":"10.1016\/S0022-3476(97)70353-6"},{"key":"2021120822540676900_R41","doi-asserted-by":"crossref","unstructured":"Tonstad S, Knudtzon J, Sivertsen M, Refsum H, Ose L. Efficacy and safety of cholestyramine therapy in peripubertal and prepubertal children with familial hypercholesterolemia. J Pediatr.\u20081996;129(1):42\u201349","DOI":"10.1016\/S0022-3476(96)70188-9"},{"key":"2021120822540676900_R42","doi-asserted-by":"crossref","unstructured":"Tonstad S, Ose L. Colestipol tablets in adolescents with familial hypercholesterolaemia. Acta Paediatr.\u20081996;85(9):1080\u20131082","DOI":"10.1111\/j.1651-2227.1996.tb14221.x"}],"container-title":["Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/123\/2\/458\/1124310\/zpe00209000458.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/123\/2\/458\/1124310\/zpe00209000458.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,9]],"date-time":"2021-12-09T02:48:56Z","timestamp":1639018136000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.aap.org\/pediatrics\/article\/123\/2\/458\/69311\/Spectrum-and-Management-of-Hypertriglyceridemia"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,2,1]]},"references-count":42,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2009,2,1]]},"published-print":{"date-parts":[[2009,2,1]]}},"URL":"https:\/\/doi.org\/10.1542\/peds.2008-0367","relation":{},"ISSN":["0031-4005","1098-4275"],"issn-type":[{"value":"0031-4005","type":"print"},{"value":"1098-4275","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,2,1]]}}}